AU7398200A - Chlamydia antigens and corresponding dna fragments and uses thereof - Google Patents

Chlamydia antigens and corresponding dna fragments and uses thereof

Info

Publication number
AU7398200A
AU7398200A AU73982/00A AU7398200A AU7398200A AU 7398200 A AU7398200 A AU 7398200A AU 73982/00 A AU73982/00 A AU 73982/00A AU 7398200 A AU7398200 A AU 7398200A AU 7398200 A AU7398200 A AU 7398200A
Authority
AU
Australia
Prior art keywords
dna fragments
corresponding dna
chlamydia antigens
chlamydia
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU73982/00A
Inventor
Pamela Dunn
Andrew D. Murdin
Raymond P. Oomen
Joe Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Aventis Pasteur Ltd
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur Ltd, Aventis Pasteur SA filed Critical Aventis Pasteur Ltd
Publication of AU7398200A publication Critical patent/AU7398200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C12N9/107—1,4-Alpha-glucan branching enzyme (2.4.1.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU73982/00A 1999-09-17 2000-09-15 Chlamydia antigens and corresponding dna fragments and uses thereof Abandoned AU7398200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15446199P 1999-09-17 1999-09-17
US60/154461 1999-09-17
PCT/CA2000/001085 WO2001021810A1 (en) 1999-09-17 2000-09-15 Chlamydia antigens and corresponding dna fragments and uses thereof

Publications (1)

Publication Number Publication Date
AU7398200A true AU7398200A (en) 2001-04-24

Family

ID=22551451

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73982/00A Abandoned AU7398200A (en) 1999-09-17 2000-09-15 Chlamydia antigens and corresponding dna fragments and uses thereof

Country Status (2)

Country Link
AU (1) AU7398200A (en)
WO (1) WO2001021810A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2340499T3 (en) 2001-06-05 2010-06-04 Curevac Gmbh TUMOR ANTIGEN ARNM STABILIZED WITH AN INCREASED G / C CONTENT.
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
WO2003059381A2 (en) * 2002-01-18 2003-07-24 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
EP2396425A2 (en) * 2009-02-13 2011-12-21 Institut National De La Sante Et De La Recherche Medicale Bacterial dna as markers of cardiovascular and/or metabolic disease
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (en) 2011-10-03 2021-10-07 Modernatx, Inc. MODIFIED NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS AND USES THEREOF
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
PL2922554T3 (en) 2012-11-26 2022-06-20 Modernatx, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
MA42502A (en) 2015-07-21 2018-05-30 Modernatx Inc VACCINES AGAINST INFECTIOUS DISEASE
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
WO2017070601A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
MA46766A (en) 2016-11-11 2019-09-18 Modernatx Inc INFLUENZA VACCINE
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS VACCINE
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. Zika virus rna vaccines
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA VACCINES
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
KR20220156933A (en) 2020-03-23 2022-11-28 에이치디티 바이오 코포레이션 Compositions and methods for delivery of RNA
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
WO2023048760A1 (en) * 2021-09-22 2023-03-30 Hdt Bio Corp. Rna vaccines against infectious diseases
JP2024535354A (en) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Cancer treatment compositions and uses thereof
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536958A (en) * 1997-11-21 2002-11-05 ジェンセット Chlamydiapneumoniae genomic sequences and polypeptides, fragments thereof, and their use especially for the diagnosis, prevention and treatment of infectious diseases

Also Published As

Publication number Publication date
WO2001021810A1 (en) 2001-03-29
WO2001021810B1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
AU7398200A (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU3760100A (en) Immunostimulatory nucleic acids and antigens
AU2001287430A1 (en) Moraxella polypeptides and corresponding dna fragments and uses thereof
AU8173098A (en) Neuroprotective methods and reagents
AU2138501A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2001248176A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU2001248172A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU2001248171A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU3072500A (en) Rhamnosyl-transferase gene and uses thereof
AU2138601A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
AU5245900A (en) Novel protein and dna thereof
AU2001248178A1 (en) Chlamydia transmembrane protein as antigen, corresponding dna fragments and uses thereof
AU2001274566A1 (en) Novel protein and dna thereof
AU1891301A (en) Novel polypeptide and dna thereof
AU2001285155A1 (en) Polymorphic dna fragments and uses thereof
AU2002216863A1 (en) Streptococcus pyogenes antigens and corresponding DNA fragments
AU1375501A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
AU5668500A (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU7398400A (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU7398300A (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU1375701A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
AU7398600A (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU7398700A (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU1375601A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2225401A (en) Novel protein and dna thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase